LEXINGTON, Mass., - September 2, 2004 - Synta Pharmaceuticals Corp., an emerging pharmaceutical company, today announced that Safi Bahcall, Ph.D., President and Chief Executive Officer, will present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference. Dr. Bahcall will provide a corporate overview and an update on the Company's clinical pipeline. The presentation will be delivered at 3:50 p.m. EDT on Thursday, September 9, 2004 from the Four Seasons Hotel in Boston, Massachusetts.
Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing products for extending and enhancing the lives of patients with severe medical conditions. Synta has a diverse pipeline of first-in-class, small-molecule drug candidates for the treatment of major immune disorders and cancers, with two lead products in multiple Phase 2 clinical trials. All clinical candidates were developed internally, and Synta fully owns all rights in all indications and markets. Synta developed as a buyout of the U.S. subsidiary of a large Japanese pharmaceutical company in 2002 and, as a result, has an experienced and fully-integrated drug discovery and development operation. Synta has raised over $128 million in private financing in the last three years to support its plans. For more information, please see www.syntapharma.com.